Product Details
M-Betahistine
Betahistine Dihydrochloride8 mg
Tablet
DIN/PIN/NPN
02519682
Manufacturer
Mantra Pharma Inc.
Formulary Listing Date
2022-05-31
Unit Price
0.2259
Amount MOH Pays
0.2259
Coverage Status
Off-Formulary Interchangeable Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
N07CA01
Interchangeable Products
| DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
|---|---|---|---|
| 02280183 | Teva-Betahistine | 0.2259 | 0.2259 |
| 02240601 | Serc | NA | NA |
| 02449145 | Auro-Betahistine | 0.2070 | 0.2070 |
| 02519682 | M-Betahistine | 0.2259 | 0.2259 |
| 02538121 | Mint-Betahistine | 0.2259 | 0.2259 |
| 02544911 | NRA-Betahistine | 0.2259 | 0.2259 |
LU Clinical Criteria
NOEAP Criteria
| Therapeutic Class | Reimbursement Criteria |
|---|---|
| Unclassified EAP Drugs | These drugs are not currently listed in the Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs – August 8, 2023 Edition Physicians may wish to contact the EAP directly by phone at 416-327-8109 or 1-866-811-9893 or by email at EAPFeedback.MOH@ontario.ca to see if an unlisted drug product and/or indication may be considered for EAP funding. |